Jim Cramer: Why Johnson & Johnson is Having a Strong Year Despite Healthcare Weakness

Johnson & Johnson's Market Performance

• 📈 Johnson & Johnson (J&J) is highlighted as one of the few winners in the healthcare sector, ranking as the 10th best-performing stock in the S&P 500, up 21.5% for the year.
• ⚠️ This strong performance is notable given the overall weakness in healthcare and J&J's persistent litigation overhang.

Diversified Business Segments

• 💡 J&J is more than just a pharmaceutical company; its medical device business accounts for 36% of sales and provides steady growth.
• 🏥 Key areas within the medtech division include cardiovascular, orthopedic, surgery, and vision, with recent acquisitions bolstering the cardiovascular segment.
• 🚀 The company also has promising technologies in robotic surgery, neurovascular care, and digital health, though this segment is often underappreciated by investors.

Pharmaceutical Business Strength

• 💊 After spinning off its over-the-counter business, J&J's remaining pharmaceutical portfolio has a higher growth rate.
• 📉 While facing generic competition for its key drug Stelara (leading to a 39% sales decline), the pharma division has still managed to outperform sales expectations.
• 🌟 The oncology business is a major driver, with sales up 21% and projections to become the number one cancer treatment company by 2030 with $50 billion in sales.
• 🎯 Growth is also strong in immunology with drugs like Tremfya, and advancements are being made in lung and bladder cancer treatments.

Addressing Litigation and Valuation

• ⚖️ J&J has shifted its legal strategy to fight talc lawsuits one at a time in court, achieving a better track record and leading Wall Street to look past the issue.
• 🗣️ The company asserts that the talc litigation is a